Cantab seeks allies for drug tests
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.CANTAB Pharmaceuticals, the biotechnology firm developing a treatment for genital herpes, is seeking further partnerships with leading drug companies this year as it embarks on advanced testing of its products.
Cantab said it had made substantial progress last year with its treatments for genital warts and genital herpes. It had also begun clinical testing of its cervical cancer product.
The increased research and development spending of pounds 3.5m last year caused Cantab's losses to double to pounds 2.9m. The company still has pounds 20m, much of it raised in the flotation last autumn.
This year, Cantab expects to begin extensive testing of its most advanced product, LM-CD45, which combats rejection of kidneys used in transplant operations.
The cost of these 'phase III' tests will be borne by Baxter Healthcare, the large US group that accounted for all of Cantab's pounds 1m of revenue last year through licensing fees and other payments.
Alan Munro, Cantab's chief scientific officer, said he expected the phase III testing of LM-CD45 to take two years.
Duncan Moore, an analyst with Morgan Stanley, which yesterday published a report on Britain's nascent biotechnology sector, recommended that investors should favour biopharmaceutical companies - such as Cantab, Celltech and British Biotechnology - ahead of companies making diagnostic equipment.
Although they involve greater risks, he said, the potential returns are much better should they develop a successful product.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments